Sugi Predict

Sugi Predict / Compounds / SCHEMBL737635

SCHEMBL737635

SCHEMBL737635

CC1(c2ccccc2)CCNCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 4/20 0.61
▸ HTR2A P28223 1/20 0.52
▸ TACR1 P25103 3/20 0.43
▸ TSHR P16473 2/20 0.42
▸ KDM1A O60341 1/20 0.42
▸ MAOA P21397 1/20 0.42
▸ OPRK1 P41145 1/20 0.41
▸ OPRL1 P41146 1/20 0.41
▸ USP2 O75604 2/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ AKT2 P31751 1/20 0.40
▸ CYP2C9 P11712 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10007993 0.98 OPRM1 (0.59) OPRM1HTR2ATACR1TSHRKDM1A
SCHEMBL14704743 0.92 OPRM1 (0.53) OPRM1HTR2ATACR1TSHRKDM1A
SCHEMBL4331091 0.87 HTR2A (0.59) OPRM1HTR2ATACR1TSHRKDM1A
SCHEMBL27225389 0.87 HTR2A (0.59) OPRM1HTR2ATACR1TSHRKDM1A
SCHEMBL27099782 0.87 HTR2A (0.59) OPRM1HTR2ATACR1TSHRKDM1A
SCHEMBL498014 0.83 OPRM1 (0.50) OPRM1MAOAOPRK1OPRL1CYP2C9
Ammonia Solution, Strong SCHEMBL9556021 0.80 OPRM1 (0.48) OPRM1MAOAOPRK1OPRL1CYP2C9
SCHEMBL18296314 0.80 OPRM1 (0.51) OPRM1MAOACYP2D6
SCHEMBL655680 0.78 DRD2 (0.60) OPRM1CYP2D6AKT2CYP3A4CYP2C19
SCHEMBL16763544 0.78 TAAR1 (0.40) OPRM1TSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10154995-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-12-18 — — US claimed
EP-3089788-B1 SERINE/THREONINE KINASE INHIBITORS GENENTECH INC (US) 2018-10-24 — — EP claimed
US-20170348310-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-07 — — US claimed
US-9763942-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2017-09-19 — — US claimed
EP-3089788-A1 SERINE/THREONINE KINASE INHIBITORS Genentech, Inc. (US) 2016-11-09 — — EP claimed
US-20160303126-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 — — US claimed
WO-2015103133-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-07-09 — — WO claimed
CN-114948963-B Benzolactam compounds as protein kinase inhibitors 大冢制药株式会社 2025-05-27 — — CN disclosed
CN-115362151-B Arylpiperidines as monoacylglycerol lipase modulators 詹森药业有限公司 2025-02-11 — — CN disclosed
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-11-07 — — US disclosed
US-20240254083-A1 HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. 2024-08-01 — — US disclosed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 — — EP disclosed
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-06-04 — — US disclosed
WO-1998057940-A1 HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1998-12-23 — — WO disclosed
WO-1998051311-A2 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1998-11-19 — — WO disclosed
US-5767131-A TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1998-06-16 — — US disclosed
US-5681841-A PREVENTION CELL AGGREGATION KARL THOMAE GMBH (DE) 1997-10-28 — — US disclosed
WO-1994022829-A2 DIHYDROPYRIDINES AND NEW USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1994-10-13 — — WO disclosed
CN-1092769-A Cyclic urea derivatives, the method that contains the pharmaceutical composition of these compounds and prepare them THOMAE GMBH DR K (DE) 1994-09-28 — — CN disclosed
EP-0587134-A2 Cyclic urea derivatives, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1994-03-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160303126-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, TTBK1, MAP3K11 OPRM1 2547/4885HTR2A 4135/4885TACR1 2550/4885
US-20240254083-A1 HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF TRPM2, TRPM7, TRPM8 OPRM1 148/4885HTR2A 485/4885TACR1 1080/4885
US-10154995-B2 Serine/threonine kinase inhibitors MAP3K1, TTBK1, MAP3K11 OPRM1 2547/4885HTR2A 4135/4885TACR1 2550/4885
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation DGKK, DGKG, DGKA OPRM1 4717/4885HTR2A 4352/4885TACR1 3978/4885
US-20170348310-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, TTBK1, MAP3K11 OPRM1 2547/4885HTR2A 4135/4885TACR1 2550/4885
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 OPRM1 570/4885HTR2A 3719/4885TACR1 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.